8-K Announcements
6Material company update
Mar 3, 2026·SEC
Material company update
Dec 15, 2025·SEC
Material company update
Nov 10, 2025·SEC
Arcturus Therapeutics Holdings Inc.(ARCT)Earnings, Financials & Key Ratios
ARCT•NASDAQ
$8.41
$239M mkt cap·Price updated May 6, 2026
AboutArcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.Show more
- Revenue$67M-51.4%
- EBITDA-$72M+21.9%
- Net Income-$66M+18.7%
- EPS (Diluted)-2.40+20.0%
- Gross Margin95.5%-4.5%
- EBITDA Margin-107.01%-60.7%
- Operating Margin-111.51%-61.3%
- Net Margin-97.86%-67.3%
- ROE-28.92%+7.2%
- ROIC-277.1%+4.9%
- Debt/Equity0.12-1.4%
ARCT Key Insights
Arcturus Therapeutics Holdings Inc. (ARCT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 47.8%
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ARCT Price & Volume
Arcturus Therapeutics Holdings Inc. (ARCT) stock price & volume — 10-year historical chart
Loading chart...
ARCT Growth Metrics
Arcturus Therapeutics Holdings Inc. (ARCT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years27.04%
5 Years47.77%
3 Years-31.13%
TTM-46.44%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM20.27%
Return on Capital
10 Years-34.7%
5 Years-27.09%
3 Years-27.69%
Last Year-29.2%
ARCT Recent Earnings
Arcturus Therapeutics Holdings Inc. (ARCT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Mar 3, 2026EPS
$1.03
Est $0.92
-12.0%
Revenue
$7M
Est $16M
-54.7%
Q4 2025
Nov 10, 2025EPS
$0.49
Est $0.80
+38.7%
Revenue
$17M
Est $16M
+7.0%
Q3 2025
Aug 11, 2025EPS
$0.34
Est $1.11
+69.4%
Revenue
$25M
Est $18M
+33.6%
Q2 2025
May 12, 2025EPS
$0.52
Est $1.58
+67.1%
Revenue
$29M
Est $23M
+25.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 3, 2026 | $1.03vs $0.92-12.0% | $7Mvs $16M-54.7% |
| Q4 2025 | Nov 10, 2025 | $0.49vs $0.80+38.7% | $17Mvs $16M+7.0% |
| Q3 2025 | Aug 11, 2025 | $0.34vs $1.11+69.4% | $25Mvs $18M+33.6% |
| Q2 2025 | May 12, 2025 | $0.52vs $1.58+67.1% | $29Mvs $23M+25.8% |
Based on last 12 quarters of dataView full earnings history →
ARCT Peer Comparison
Arcturus Therapeutics Holdings Inc. (ARCT) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MRNA | 18.52B | 46.71 | -6.43 | -39.23% | -143.55% | -36.73% | 0.22 | |
 BNTX | 24B | 95.50 | -18.04 | 0.2% | -39.6% | -6.03% | 1.32% | 0.01 |
 NTLA | 1.55B | 13.31 | -3.49 | -100% | -61.47% | 0.14 | ||
 CRSP | 4.92B | 52.38 | -8.10 | -89.97% | -13.29% | -25.49% | 0.11 | |
 BEAM | 2.97B | 28.90 | -35.68 | 120.01% | -57.24% | -7.31% | 0.24 | |
 ALNY | 40.18B | 301.11 | 129.23 | 65.19% | 13.46% | 98.29% | 1.16% | 1.62 |
 IONS | 12.44B | 75.25 | -31.62 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ARWR | 10.49B | 74.93 | -6141.80 | 232.58% | 18.54% | 35.64% | 1.5% | 0.73 |
Compare ARCT vs Peers
Arcturus Therapeutics Holdings Inc. (ARCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARCT Income Statement
Arcturus Therapeutics Holdings Inc. (ARCT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 13M | 15.75M | 20.79M | 9.54M | 12.36M | 205.75M | 157.75M | 138.39M | 67.22M |
| Revenue Growth % | -36.23% | 21.2% | 31.97% | -54.12% | 29.56% | 1564.82% | -23.33% | -12.27% | -51.43% |
| Cost of Goods Sold | 410K | 16.98M | 0 | 55.95M | 0 | 0 | 0 | 0 | 3.02M |
| COGS % of Revenue | 3.15% | 107.8% | - | 586.5% | - | - | - | - | 4.5% |
| Gross Profit | 12.59M▲ 0% | -1.23M▼ 109.8% | 20.79M▲ 1791.5% | -46.41M▼ 323.2% | 12.36M▲ 126.6% | 205.75M▲ 1564.8% | 157.75M▼ 23.3% | 138.39M▼ 12.3% | 64.2M▼ 53.6% |
| Gross Margin % | 96.85% | -7.8% | 100% | -486.5% | 100% | 100% | 100% | 100% | 95.5% |
| Gross Profit Growth % | -37.34% | -109.76% | 1791.54% | -323.23% | 126.63% | 1564.82% | -23.33% | -12.27% | -53.61% |
| Operating Expenses | 23.49M | 37.56M | 46.3M | 25.12M | 215.21M | 193.58M | 235.95M | 234.06M | 139.15M |
| OpEx % of Revenue | 180.72% | 238.46% | 222.72% | 263.31% | 1741.33% | 94.08% | 149.58% | 169.13% | 207.01% |
| Selling, General & Admin | 7.57M | 20.58M | 12.66M | 25.12M | 41.45M | 46.07M | 52.87M | 52.82M | 46.08M |
| SG&A % of Revenue | 58.26% | 130.65% | 60.91% | 263.31% | 335.39% | 22.39% | 33.52% | 38.17% | 68.55% |
| Research & Development | 15.92M | 16.98M | 33.64M | 57.85M | 173.76M | 147.75M | 192.13M | 195.16M | 112.21M |
| R&D % of Revenue | 122.47% | 107.8% | 161.82% | 606.42% | 1405.94% | 71.81% | 121.8% | 141.02% | 166.93% |
| Other Operating Expenses | -348K | 0 | 0 | -57.85M | 0 | -244K | -9.05M | -13.92M | -19.14M |
| Operating Income | -10.49M▲ 0% | -21.81M▼ 107.9% | -25.51M▼ 17.0% | -71.52M▼ 180.3% | -202.85M▼ 183.6% | 12.18M▲ 106.0% | -78.2M▼ 742.2% | -95.67M▼ 22.3% | -74.95M▲ 21.7% |
| Operating Margin % | -80.72% | -138.46% | -122.72% | -749.81% | -1641.33% | 5.92% | -49.58% | -69.13% | -111.51% |
| Operating Income Growth % | 58.31% | -107.88% | -16.97% | -180.34% | -183.61% | 106% | -742.24% | -22.33% | 21.65% |
| EBITDA | -10.08M | -21.23M | -24.83M | -70.64M | -201.66M | 13.7M | -75.25M | -92.13M | -71.93M |
| EBITDA Margin % | -77.57% | -134.76% | -119.43% | -740.56% | -1631.68% | 6.66% | -47.7% | -66.57% | -107.01% |
| EBITDA Growth % | 59.47% | -110.56% | -16.96% | -184.51% | -185.47% | 106.8% | -649.1% | -22.43% | 21.92% |
| D&A (Non-Cash Add-back) | 410K | 582K | 684K | 882K | 1.19M | 1.53M | 2.96M | 3.54M | 3.02M |
| EBIT | -10.75M | -21.3M | -25.14M | -71.52M | -202.85M | 12.18M | -27.12M | -80.94M | -74.95M |
| Net Interest Income | -61K | 328K | -446K | -361K | -1.92M | -420K | 16.59M | 15.2M | 10.1M |
| Interest Income | 89K | 514K | 408K | 470K | 753K | 2.58M | 17.36M | 15.2M | 10.1M |
| Interest Expense | 150K | 186K | 854K | 831K | 2.67M | 3M | 767K | 0 | 0 |
| Other Income/Expense | -409K | 26K | -478K | -624K | -822K | -1.53M | 50.31M | 14.72M | 9.17M |
| Pretax Income | -10.9M▲ 0% | -21.79M▼ 99.8% | -25.99M▼ 19.3% | -72.15M▼ 177.6% | -203.67M▼ 182.3% | 10.64M▲ 105.2% | -27.89M▼ 362.0% | -80.94M▼ 190.2% | -65.78M▲ 18.7% |
| Pretax Margin % | -83.87% | -138.29% | -125.02% | -756.35% | -1647.98% | 5.17% | -17.68% | -58.49% | -97.86% |
| Income Tax | 1K | 212K | 0 | 0 | 0 | 1.29M | 1.83M | -4K | 0 |
| Effective Tax Rate % | -0.01% | -0.97% | 0% | 0% | 0% | 12.17% | -6.58% | 0% | 0% |
| Net Income | -10.9M▲ 0% | -21.79M▼ 99.8% | -25.99M▼ 19.3% | -72.15M▼ 177.6% | -203.67M▼ 182.3% | 9.35M▲ 104.6% | -29.73M▼ 417.9% | -80.94M▼ 172.3% | -65.78M▲ 18.7% |
| Net Margin % | -83.87% | -138.29% | -125.02% | -756.35% | -1647.98% | 4.54% | -18.84% | -58.49% | -97.86% |
| Net Income Growth % | 55.69% | -99.83% | -19.31% | -177.59% | -182.3% | 104.59% | -417.95% | -172.3% | 18.73% |
| Net Income (Continuing) | -10.9M | -21.79M | -25.99M | -72.15M | -203.67M | 9.35M | -29.73M | -80.94M | -65.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.53▲ 0% | -2.16▲ 38.8% | -2.13▲ 1.4% | -3.55▼ 66.7% | -7.74▼ 118.0% | 0.35▲ 104.5% | -1.12▼ 420.0% | -3.00▼ 167.9% | -2.40▲ 20.0% |
| EPS Growth % | 43.52% | 38.81% | 1.39% | -66.67% | -118.03% | 104.52% | -420% | -167.86% | 20% |
| EPS (Basic) | -3.53 | -2.16 | -2.13 | -3.55 | -7.74 | 0.35 | -1.12 | -3.00 | -2.40 |
| Diluted Shares Outstanding | 3.09M | 10.07M | 12.07M | 20.3M | 26.32M | 27.09M | 26.63M | 27M | 27.39M |
| Basic Shares Outstanding | 3.09M | 10.07M | 12.07M | 20.3M | 26.32M | 26.45M | 26.63M | 27M | 27.39M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ARCT Balance Sheet
Arcturus Therapeutics Holdings Inc. (ARCT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 50.87M | 41.83M | 74.29M | 467.79M | 378.96M | 403.33M | 386.59M | 305.98M | 241.45M |
| Cash & Short-Term Investments | 48.57M | 36.71M | 71.35M | 462.89M | 370.49M | 391.88M | 292M | 237.03M | 230.91M |
| Cash Only | 24.96M | 36.71M | 71.35M | 462.89M | 370.49M | 391.88M | 292M | 237.03M | 230.91M |
| Short-Term Investments | 23.61M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 480K | 4.48M | 2.18M | 2.13M | 3.37M | 2.76M | 32.06M | 3.97M | 5.56M |
| Days Sales Outstanding | 13.48 | 103.83 | 38.26 | 81.31 | 99.44 | 4.9 | 74.19 | 10.48 | 30.21 |
| Inventory | 1.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 1.3K | - | - | - | - | - | - | - | - |
| Other Current Assets | 756K | 0 | 0 | 0 | 0 | 8.69M | 55M | 64.98M | 4.97M |
| Total Non-Current Assets | 1.16M | 2.37M | 7.85M | 8.67M | 13.85M | 47.05M | 42.81M | 38.09M | 29.7M |
| Property, Plant & Equipment | 1.05M | 1.98M | 7.48M | 8.56M | 11.26M | 44.96M | 40.93M | 36.2M | 27.82M |
| Fixed Asset Turnover | 12.39x | 7.98x | 2.78x | 1.11x | 1.10x | 4.58x | 3.85x | 3.82x | 2.42x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 107K | 288K | 263K | 0 | 515K | 0 | 1.89M | 0 | 1.89M |
| Other Non-Current Assets | 107K | 107K | 107K | 107K | 2.08M | 2.09M | 0 | 1.89M | 0 |
| Total Assets | 52.02M▲ 0% | 44.2M▼ 15.0% | 82.14M▲ 85.9% | 476.46M▲ 480.0% | 392.81M▼ 17.6% | 450.39M▲ 14.7% | 429.4M▼ 4.7% | 344.07M▼ 19.9% | 271.15M▼ 21.2% |
| Asset Turnover | 0.25x | 0.36x | 0.25x | 0.02x | 0.03x | 0.46x | 0.37x | 0.40x | 0.25x |
| Asset Growth % | 0.88% | -15.04% | 85.85% | 480.03% | -17.55% | 14.66% | -4.66% | -19.87% | -21.19% |
| Total Current Liabilities | 11.04M | 12.58M | 21.32M | 49.52M | 99.54M | 126.98M | 81.99M | 65.49M | 36.38M |
| Accounts Payable | 1.79M | 2.4M | 5.79M | 10.77M | 10.06M | 7.45M | 5.28M | 7.19M | 4.24M |
| Days Payables Outstanding | 1.59K | 51.54 | - | 70.29 | - | - | - | - | 511 |
| Short-Term Debt | 0 | 0 | 0 | 1.25M | 22.47M | 60.66M | 0 | 0 | 4.21M |
| Deferred Revenue (Current) | 6.46M | 6.27M | 0 | 0 | 0 | 36.12M | 47.34M | 21.93M | 8.25M |
| Other Current Liabilities | 981K | 8.53M | 10.35M | 24.69M | 46.26M | 4.04M | 18.5M | 13.3M | 19.68M |
| Current Ratio | 4.61x | 3.33x | 3.48x | 9.45x | 3.81x | 3.18x | 4.72x | 4.67x | 6.64x |
| Quick Ratio | 4.48x | 3.33x | 3.48x | 9.45x | 3.81x | 3.18x | 4.72x | 4.67x | 6.64x |
| Cash Conversion Cycle | -280.3 | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 7.19M | 17.98M | 35.03M | 30.38M | 65.07M | 53.09M | 68.9M | 37.6M | 20.78M |
| Long-Term Debt | 0 | 9.91M | 14.99M | 13.85M | 40.63M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 4.85M | 4.03M | 4.5M | 30.22M | 25.91M | 25M | 20.78M |
| Deferred Tax Liabilities | 26.61M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 8.07M | 15.18M | 12.51M | 19.93M | 2.8M | 497K | 0 | 0 |
| Total Liabilities | 18.23M | 30.56M | 56.35M | 79.9M | 164.6M | 180.07M | 150.89M | 103.09M | 57.16M |
| Total Debt | 0 | 9.91M | 20.67M | 20.75M | 69.15M | 94.75M | 30.22M | 28.55M | 25M |
| Net Debt | -24.96M | -26.8M | -50.68M | -442.14M | -301.35M | -297.13M | -261.79M | -208.48M | -205.91M |
| Debt / Equity | - | 0.73x | 0.80x | 0.05x | 0.30x | 0.35x | 0.11x | 0.12x | 0.12x |
| Debt / EBITDA | - | - | - | - | - | 6.91x | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | -21.68x | - | - | - |
| Interest Coverage | -71.67x | -114.50x | -29.43x | -86.07x | -75.86x | 4.06x | -35.36x | - | - |
| Total Equity | 33.79M▲ 0% | 13.64M▼ 59.6% | 25.79M▲ 89.1% | 396.55M▲ 1437.5% | 228.21M▼ 42.5% | 270.31M▲ 18.4% | 278.51M▲ 3.0% | 240.98M▼ 13.5% | 213.99M▼ 11.2% |
| Equity Growth % | -28.44% | -59.63% | 89.06% | 1437.5% | -42.45% | 18.45% | 3.03% | -13.48% | -11.2% |
| Book Value per Share | 10.95 | 1.35 | 2.14 | 19.53 | 8.67 | 9.98 | 10.46 | 8.93 | 7.81 |
| Total Shareholders' Equity | 33.79M | 13.64M | 25.79M | 396.55M | 228.21M | 270.31M | 278.51M | 240.98M | 213.99M |
| Common Stock | 212K | 214K | 15K | 26K | 26K | 27K | 27K | 27K | 28K |
| Retained Earnings | -23.09M | -44.87M | -71.67M | -143.82M | -347.49M | -338.14M | -367.87M | -448.81M | -514.59M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARCT Cash Flow Statement
Arcturus Therapeutics Holdings Inc. (ARCT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -460K | -20.76M | -6.45M | -42.86M | -135.04M | 31.99M | -18.1M | -59.75M | -74.27M |
| Operating CF Margin % | -3.54% | -131.78% | -31% | -449.32% | -1092.67% | 15.55% | -11.47% | -43.17% | -110.49% |
| Operating CF Growth % | 97.61% | -4413.04% | 68.95% | -565.03% | -215.07% | 123.69% | -156.57% | -230.11% | -24.31% |
| Net Income | -10.9M | -21.79M | -25.99M | -72.15M | -203.67M | 9.35M | -29.73M | -80.94M | -65.78M |
| Depreciation & Amortization | 410K | 582K | 684K | 882K | 1.19M | 1.53M | 2.96M | 3.54M | 3.02M |
| Stock-Based Compensation | 2.17M | 1.26M | 1.98M | 6.76M | 28.91M | 30.61M | 34.65M | 37.99M | 25.41M |
| Deferred Taxes | 0 | 302K | 25K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 498K | 38K | 873K | 425K | 5.9M | 3.06M | -33.36M | 471K | 2.28M |
| Working Capital Changes | 7.36M | -1.16M | 15.98M | 21.22M | 32.63M | -12.56M | 7.38M | -20.81M | -39.2M |
| Change in Receivables | 3.15M | -4M | 2.3M | 54K | -1.24M | 603K | -29.3M | 28.09M | -1.59M |
| Change in Inventory | -306K | 2.11M | 1.55M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.54M | 578K | 3.15M | 4.81M | -769K | -3.11M | -2.24M | 1.92M | -2.96M |
| Cash from Investing | 10.36M | 22.13M | -818K | -1.74M | -3.41M | -7.73M | -2.9M | -648K | -230K |
| Capital Expenditures | -251K | -1.48M | -818K | -1.74M | -3.41M | -7.73M | -2.9M | -648K | -230K |
| CapEx % of Revenue | 1.93% | 9.38% | 3.93% | 18.26% | 27.56% | 3.75% | 1.84% | 0.47% | 0.34% |
| Acquisitions | 29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 29K | 23.61M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 7M | 10.2M | 41.91M | 436.14M | 48.02M | -2.86M | -24.09M | 5.42M | 13.38M |
| Debt Issued (Net) | 5.65M | 9.87M | 4.95M | 0 | 46.6M | -5M | -27.36M | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 21.28M | 423.82M | 515K | 411K | 609K | 682K | 13.38M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.35M | 332K | 15.68M | 12.33M | 902K | 1.73M | 2.67M | 4.74M | 0 |
| Net Change in Cash | 16.89M▲ 0% | 11.58M▼ 31.5% | 34.64M▲ 199.2% | 391.54M▲ 1030.2% | -90.43M▼ 123.1% | 21.41M▲ 123.7% | -45.09M▼ 310.6% | -54.98M▼ 21.9% | -61.12M▼ 11.2% |
| Free Cash Flow | -711K▲ 0% | -22.24M▼ 3027.7% | -7.26M▲ 67.3% | -44.6M▼ 514.1% | -138.45M▼ 210.4% | 24.27M▲ 117.5% | -21M▼ 186.5% | -60.4M▼ 187.6% | -74.27M▼ 23.0% |
| FCF Margin % | -5.47% | -141.17% | -34.94% | -467.59% | -1120.23% | 11.79% | -13.31% | -43.64% | -110.49% |
| FCF Growth % | 96.32% | -3027.71% | 67.34% | -514.11% | -210.4% | 117.53% | -186.54% | -187.6% | -22.98% |
| FCF per Share | -0.23 | -2.21 | -0.60 | -2.20 | -5.26 | 0.90 | -0.79 | -2.24 | -2.71 |
| FCF Conversion (FCF/Net Income) | 0.04x | 0.95x | 0.25x | 0.59x | 0.66x | 3.42x | 0.61x | 0.74x | 1.13x |
| Interest Paid | 0 | 0 | 0 | 751K | 684K | 813K | 2.13M | 0 | 0 |
| Taxes Paid | 35K | 0 | 0 | 0 | 0 | 0 | 0 | 1.41M | 0 |
ARCT Key Ratios
Arcturus Therapeutics Holdings Inc. (ARCT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -42.22% | -26.91% | -91.85% | -131.82% | -34.17% | -65.2% | 3.75% | -10.83% | -31.16% | -28.92% |
| Return on Invested Capital (ROIC) | -38.63% | -29.21% | - | - | - | - | - | -350.72% | -291.53% | -277.1% |
| Gross Margin | 98.56% | 96.85% | -7.8% | 100% | -486.5% | 100% | 100% | 100% | 100% | 95.5% |
| Net Margin | -120.71% | -83.87% | -138.29% | -125.02% | -756.35% | -1647.98% | 4.54% | -18.84% | -58.49% | -97.86% |
| Debt / Equity | 0.00x | - | 0.73x | 0.80x | 0.05x | 0.30x | 0.35x | 0.11x | 0.12x | 0.12x |
| Interest Coverage | -4.21x | -71.67x | -114.50x | -29.43x | -86.07x | -75.86x | 4.06x | -35.36x | - | - |
| FCF Conversion | 0.78x | 0.04x | 0.95x | 0.25x | 0.59x | 0.66x | 3.42x | 0.61x | 0.74x | 1.13x |
| Revenue Growth | 232.06% | -36.23% | 21.2% | 31.97% | -54.12% | 29.56% | 1564.82% | -23.33% | -12.27% | -51.43% |
ARCT SEC Filings & Documents
Arcturus Therapeutics Holdings Inc. (ARCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
ARCT Frequently Asked Questions
Arcturus Therapeutics Holdings Inc. (ARCT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Arcturus Therapeutics Holdings Inc. (ARCT) reported $74.1M in revenue for fiscal year 2025.
Arcturus Therapeutics Holdings Inc. (ARCT) saw revenue decline by 51.4% over the past year.
Arcturus Therapeutics Holdings Inc. (ARCT) reported a net loss of $65.8M for fiscal year 2025.
Dividend & Returns
Arcturus Therapeutics Holdings Inc. (ARCT) has a return on equity (ROE) of -28.9%. Negative ROE indicates the company is unprofitable.
Arcturus Therapeutics Holdings Inc. (ARCT) had negative free cash flow of $74.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More ARCT
Arcturus Therapeutics Holdings Inc. (ARCT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates